Successful Targeted Therapy of Refractory Pediatric Fusion-Positive Secretory Breast Carcinoma

about

Successful Targeted Therapy of Refractory Pediatric Fusion-Positive Secretory Breast Carcinoma

Item

http://www.wikidata.org/entity/Q57943504

description

scientific article published on 18 August 2017

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2017

@uk

name

Successful Targeted Therapy of ...... ive Secretory Breast Carcinoma

@en

Successful Targeted Therapy of ...... ive Secretory Breast Carcinoma

@nl

type

Item

label

Successful Targeted Therapy of ...... ive Secretory Breast Carcinoma

@en

Successful Targeted Therapy of ...... ive Secretory Breast Carcinoma

@nl

prefLabel

Successful Targeted Therapy of ...... ive Secretory Breast Carcinoma

@en

Successful Targeted Therapy of ...... ive Secretory Breast Carcinoma

@nl

P1476

Successful Targeted Therapy of ...... ive Secretory Breast Carcinoma

@en

P2093

Ahmet Zehir

http://www.w3.org/2001/XMLSchema#string

Alexander Drilon

http://www.w3.org/2001/XMLSchema#string

Andrew L Kung

http://www.w3.org/2001/XMLSchema#string

Ben H Park

http://www.w3.org/2001/XMLSchema#string

David M Hyman

http://www.w3.org/2001/XMLSchema#string

Elli Papaemmanuil

http://www.w3.org/2001/XMLSchema#string

Gerald Behr

http://www.w3.org/2001/XMLSchema#string

Gunes Gundem

http://www.w3.org/2001/XMLSchema#string

Heather Geiger

http://www.w3.org/2001/XMLSchema#string

José Baselga

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated map of genetic variation from 1,092 human genomes

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

The genomic landscape of pediatric Ewing sarcoma.

TRKing down an old oncogene in a new era of targeted therapy

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

Signatures of mutational processes in human cancer

The life history of 21 breast cancers

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

P31

scholarly article

P356

10.1200/PO.17.00034

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Jaclyn F Hechtman

Robert B. Darnell

P577

2017-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29623306

http://www.w3.org/2001/XMLSchema#string

P932

5880290

http://www.w3.org/2001/XMLSchema#string